Dachille Douglas A. 4

What Happened

• Douglas A. Dachille, a director of BridgeBio Pharma, received equity awards on 2026-06-22: 3,990 restricted stock units (RSUs) and 5,277 RSUs recorded as a derivative grant. Both awards were granted at $0.00 per unit (no cash paid). Total units granted = 9,267 RSUs; current reported value at grant = $0.

Key Details

• Transaction date: 2026-06-22; Form 4 filed 2026-06-24 (timely).
• Grants: 3,990 RSUs (non-derivative) and 5,277 RSUs (derivative) at $0.00.
• Vesting: RSUs vest in full on 2027-06-22, subject to continued service on the board.
• Derivative explanation: Each RSU represents a contingent right to receive one share of common stock upon vesting.
• Ownership note: The 5,277 units are owned directly by The Dachille 2012-1 Family Trust for the benefit of the reporting person’s children; the reporting person disclaims beneficial ownership of those trust-held securities.
• Shares owned after transaction: Not specified in the filing.
• Other: Exhibit 24 (Power of Attorney) attached to the filing.

Context

• These are time-based RSU grants (award), not purchases or sales — they do not require cash from the director and do not signal an immediate market action. The awards simply give the right to receive shares if the director remains in service through the 2027 vest date.